S&P Equity Research downgrades PDL Biopharma (Nasdaq: PDLI) from Buy to Hold.

S&P analyst, S. Silver, says, "Q4 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE